{"entity":{"id":"peptide-drug-conjugate","kind":"technology","name":"Peptide-drug & small-molecule-drug conjugates","aka":[],"tldr":"Like an ADC but with a small targeting peptide instead of an antibody, so it penetrates tumours faster and is cheaper to make.","summary":"Peptide-drug conjugates replace the antibody of an ADC with a short or bicyclic peptide that binds the target, giving rapid tumour penetration and renal clearance, with a short half-life that reduces systemic exposure and cheaper synthesis. Examples include melflufen (Pepaxto, withdrawn in the US), lutetium radioligands (technically peptide-radionuclide conjugates), and clinical-stage PDCs such as BT8009 zelenectide pevedotin, a Nectin-4 Bicycle toxin conjugate, and CBX-12, an exatecan-SMDC. Bicycle's zelenectide pevedotin is in phase 2/3 in urothelial cancer. The same short half-life that limits toxicity also limits tumour exposure, and renal toxicity is a class concern. The simple version is an ADC with a small peptide as the address label, faster to penetrate tumours and cheaper to make.","status":"approved","asOf":"2026-09-04","links":[{"label":"Cooper et al., Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (Chemical Society Reviews 2021)","url":"https://doi.org/10.1039/D0CS00556H"}],"tags":[],"related":[],"indications":[],"sections":[],"technologies":[],"targets":["nectin4"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Short peptide or bicyclic peptide binds the target; short half-life reduces systemic exposure.","strengths":["Rapid penetration, renal clearance","Cheaper synthesis"],"limitations":["Short half-life limits tumour exposure","Renal toxicity"]},"route":"/technologies/peptide-drug-conjugate/","neighbours":{"target":[{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/"},{"id":"sortilin","kind":"target","name":"Sortilin (SORT1)","route":"/targets/sortilin/"}],"opportunity":[{"id":"opp-nectin4-imaging-urothelial","kind":"opportunity","name":"A liver-cleared Nectin-4 tracer for urothelial cancer","route":"/opportunities/opp-nectin4-imaging-urothelial/"},{"id":"opp-grpr-psma-negative-prostate","kind":"opportunity","name":"GRPR imaging when the PSMA scan is negative","route":"/opportunities/opp-grpr-psma-negative-prostate/"}],"section":[{"id":"f-radioligand-therapy","kind":"section","name":"Radioligand therapy","route":"/fronts/f-radioligand-therapy/"}]}}